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Preoperative anaemia is frequent in surgical patients and
increases postoperative mortality, major morbidity, and
length of hospital stay.1 Poorly controlled bleeding and surgi-
cal blood loss can also contribute to these outcomes.
Anaemia, blood loss, and liberal transfusion triggers are the
main predictors for red blood cell (RBC) transfusion.2 RBC
transfusion in turn is an additional independent predictor
for adverse outcome and has therefore been referred to as
the ‘second hit’ for the recipient.3 Transfusion outcomes
include higher mortality, more ischaemic complications,
organ dysfunction, infections, delayed wound healing, and
increased length of hospital stay.4 – 8 Transfused patients
may also be more likely to develop non-Hodgkin lymphoma.9
Interestingly, most of these complications are found after
administration of just a single RBC unit.10 11 Strict application
of the Bradford-Hill criteria strongly suggests that the link
between transfusion and adverse outcomes is causal and
not just associative.6 12
A further challenge is the surveillance for newly emerging
and re-emerging pathogens. Protozoan parasites in the
blood donor pool cause babesiosis and Chagas disease, and
transfusion-transmitted viral infections such as dengue
and chikungunya represent real threats to public health
systems.13 Recently, a transgenic mouse model demonstrated
how human tau protein from injected Alzheimer’s disease
brain extracts, spreads, and co-aggregates with endogenous
mouse tau.14 These findings suggest that tau pathology may
develop in the brain by a prion-like mechanism.15 Similar to
the pathogenesis of variant Creutzfeldt–Jakob disease (vCJD),
transfusion might play a role in one of the infective pathways.16
Transfusion of RBCs,8 the treatment of adverse transfusion
outcomes,17 and expanding surveillance systems result in
considerable financial burdens for all health systems in the
developed world.
Patient blood management (PBM) has recently been
described as a concept pre-empting and significantly redu-
cing the resort to transfusions by addressing anaemia,
blood loss, and hypoxia as modifiable risk factors that may
result in transfusion long before transfusion may even be
considered. The three pillars of PBM—detection and treat-
ment of preoperative anaemia, reduction in perioperative
blood loss, and harnessing and optimizing the patient-
specific physiological reserve of anaemia (including restrict-
ive haemoglobin transfusion triggers)18 (Table 1)—have
been proposed for years as a new standard of care to avoid
the above described complications and costs.18 PBM was
also adopted by the World Health Organization (WHA63.12)
in 2010 as a principle to improve transfusion safety. Since
then, the WHO has been urging member states ‘to
promote the availability of transfusion alternatives including,
where appropriate, autologous transfusion and patient blood
management’.
In Europe, however, few PBM programmes have been
started so far. Kotze´ and colleagues thus have to be congra-
tulated for their study in the British Journal of Anaesthesia
describing the implementation of such a programme in a
Yorkshire hospital.19 Their programme was developed in
three stages: first, they analysed the anaemia prevalence
and transfusion rates in their centre and explored the local
associations between preoperative haemoglobin, RBC
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transfusion, and hospital outcomes, including the length of
stay and re-admission rate after discharge; secondly, they
designed their local treatment algorithm; thirdly, they pro-
spectively collected post-implementation data including
costs.
With their PBM programme, they succeeded in significant-
ly reducing the anaemia prevalence from 26% to 10%, peri-
operative RBC loss by 20%, transfusion rate for total hip
arthroplasty from 23% to 8%, and in total knee arthroplasty
from 8% to 0%.19 In addition, they succeeded in reducing the
length of hospital stay from 6 to 5 days in total hip arthro-
plasty and from 6 to 4 days in total knee arthroplasty, and
to reduce the 90 days re-admission rate from 14% to 8%.
These are indeed impressive results.
Drug costs were low (£16 695) and largely offset by the
costs of avoided RBC transfusion (£12 625). However, as
acknowledged by the authors, they used blood bank acquisi-
tion costs for RBC for their calculation and not activity-based
costs which are three to four times higher.8 It is important to
note that they did not account for 404 fewer days of hospi-
talization and that 16 fewer patients were re-admitted
within 90 days after operation. Using an estimated average
cost of £400 per hospital stay day in the UK and several thou-
sand pounds for re-admissions, the PBM team would have
achieved a net saving of over £160 000. Shifting the em-
phasis from product centred transfusion practice to PBM
represents a win-win situation that is extremely rare in
medicine: patients get home sooner, hospitals generate
cost savings by using fewer resources per patient, and physi-
cians achieve better clinical outcomes.
Optimal PBM includes the detection of anaemia sufficient-
ly in advance of the planned operation which certainly is a
logistical challenge. A very promising approach, as used by
this group,19 is to include the general practitioner in the pre-
operative optimization of the patient and to use a simple al-
gorithm, based on haemoglobin and ferritin measurements
(http://www.nba.gov.au/guidelines/module2/index.html#guide
lines/module2/po-v2a.pdf, accessed 11 March 2011),19 20
to treat anaemia. In orthopaedic surgery, anaemia treat-
ment usually starts 4–8 weeks before the operation; in
cardiac surgery, this may be more difficult but may not be
necessary. Recent studies indicate that a very short-term
treatment with erythropoiesis-stimulating agents and i.v.
iron starting only 2–0 days before surgery reduces RBC trans-
fusions and improves clinical outcome.21 22 This may be a
useful concept in orthopaedic surgery.23
For the reduction in perioperative blood loss, a bundle of
measures needs to be combined (Table 1). The most import-
ant is a meticulous surgical technique aiming at minimizing
blood loss. Discussion with surgical colleagues the disadvan-
tages of insufficient haemostasis and the advantages of
minimizing blood loss is worthwhile. Along with acute nor-
movolaemic haemodilution and cell salvage, an individua-
lized, goal-directed coagulation algorithm and the use of
anti-fibrinolytics such as tranexamic acid and, probably
soon again, aprotinin (http://www.ema.europa.eu/ema/index.
jsp?curl=pages%2Fnews_and_events%2Fnews%2F2012%2F02%
2Fnews_detail_001447.jsp&mid=WC0b01ac058004d5c1&
jsenabled=true, accessed 24 February 2012), and factor con-
centrates are important.24–26 Low haemoglobin transfusion
triggers are another important element to reduce the transfu-
sion rate. Low haemoglobin transfusion triggers, such as
,70 g litre21 in general surgical patients27 and ,80 g litre21
in elderly high-risk patients, are well tolerated.28 In selected
patients, treatment to maximize oxygenation and minimize
metabolic demand might be required to avoid transfusion.
This is a wake-up call for physicians, hospital administra-
tors, and regulators. The incidence of preoperative anaemia
is known to be high (20–40%),1 4 29 associated with increased
mortality and major morbidity,1 and associated with transfu-
sion of RBC that again increases mortality, major morbidity,
and hospital length of stay.4 – 7 10 However, too few have
changed from the transfusion-based culture. Therefore, we
all should take this study as a model and implement our own
local PBM programme—it is time to wake up!
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